Bifurcation Lesions Global Market Report 2024

Bifurcation lesions in the context of coronary arteries refer to constrictions that occur adjacent to or involve the origin of a critical side branch that one aims to preserve. This situation arises when there is an accumulation of plaque deposits, causing the artery to become too narrow, thereby hindering adequate blood flow to the heart.

The main categorizations of bifurcation lesions are one-stent and two-stent approaches. In a one-stent bifurcation lesion procedure, the side branch is provisionally stented if intervention is deemed necessary based on clinical complaints, angiographic results, or other relevant factors. In this approach, the main branch is stented first. The bifurcation angle is determined by the internal angle between the main and side branches. These types of bifurcation lesions are encountered in both coronary and peripheral vascular contexts.

The bifurcation lesions market research report is one of a series of new reports that provides bifurcation lesions market statistics, including bifurcation lesions industry global market size, regional shares, competitors with a bifurcation lesions market share, detailed bifurcation lesions market segments, market trends and opportunities, and any further data you may need to thrive in the bifurcation lesions industry. This bifurcation lesions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bifurcation lesions market size has grown strongly in recent years. It will grow from $2.47 billion in 2023 to $2.7 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth observed during the historical period in the context of bifurcation lesions can be attributed to several factors. These include the rise in the prevalence of coronary artery diseases, an increase in the geriatric population, a surge in healthcare expenditure, and overall economic growth. These factors collectively contributed to the expansion and development of interventions and procedures related to bifurcation lesions during the specified historical timeframe.

The bifurcation lesions market size is expected to see strong growth in the next few years. It will grow to $3.74 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The anticipated growth in the forecast period for interventions related to bifurcation lesions can be attributed to various factors. These include the increasing demand for minimally invasive surgeries, the expansion of healthcare infrastructure and facilities, a rising prevalence of cardiovascular diseases, and supportive government healthcare policies. Major trends expected during this period include the adoption of patient-centric approaches, the development of bioresorbable stents, the integration of artificial intelligence (AI) and machine learning in treatment approaches, and increased cross-specialty collaboration. These trends highlight significant considerations in the healthcare landscape as it evolves to meet the demands of patients and leverage advancements in medical technology.

The growth of the bifurcation lesions market is expected to be driven by the increasing geriatric population. Individuals aged 60 and above are more susceptible to heart-related issues such as heart attacks, strokes, coronary heart disease, and heart failure. Bifurcation lesions play a crucial role in treating blood clots and facilitating adequate blood flow to the heart in such cases. A report by the World Health Organization (WHO) projected that by 2030, one in six people globally would be 60 or older, and by 2050, the number of individuals aged 80 and above would increase by 426 million compared to the current population. The rise in the geriatric population is anticipated to be a significant driver for the bifurcation lesions market.

The growth of the bifurcation lesions market is further expected to be boosted by increasing healthcare expenditure. Higher healthcare spending enables healthcare facilities to invest in advanced interventional cardiology devices, including those used for treating bifurcation lesions. According to the 2021–2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services, national health spending is estimated to increase by an average of 5.1% annually, reaching nearly $6.8 trillion between 2021 and 2030. The report also anticipates an annual increase of 7.2% in Medicare spending and 5.6% in Medicaid spending during the same period. The upward trend in healthcare expenditure is a significant driver for the bifurcation lesions market.

A key trend gaining popularity in the bifurcation lesions market is the advancement in devices used in imaging and procedures. Leading companies in the market are focusing on enhancing existing devices used in imaging and procedures. For example, Advanced Bifurcation Systems (ABS), a clinical-stage medical device firm, has developed a unique bifurcation stenting solution featuring modular self-aligning stent technology. This platform aims to standardize the treatment of all bifurcation lesions in coronary angioplasties, providing a single system that reduces the need for repeat procedures and enables effective bifurcation stenting treatment. The trend towards device advancement is contributing to the growth and innovation in the bifurcation lesions market.

Leading companies in the bifurcation lesions market are actively developing innovative products such as drug-eluting coronary stent systems to expand their customer base, increase sales, and drive revenue growth. A drug-eluting coronary stent system is a specialized medical device used in interventional cardiology for the treatment of coronary artery disease. In August 2023, Medtronic PLC, an Ireland-based medical device company, introduced the Onyx Frontier drug-eluting stent (DES) to address non-left main bifurcation lesions using the provisional stenting technique. This product incorporates several design enhancements, including a dual-layer balloon, reduced crossing profile, and enhanced catheter flexibility. The improvements result in a 16% enhancement in deliverability compared to the prior-generation Resolute Onyx DES, maintaining the same level of radial strength. Onyx Frontier offers an extensive range of sizes, accommodating patient needs with diameters ranging from 2.0mm to 5.0mm, with specific sizing for the treatment of extra-large vessels, including those in the left main. The product inherits clinical data and indications from Resolute Onyx, including approval for treating bifurcation lesions, left main percutaneous coronary intervention (PCI), and a recommended one-month duration of dual antiplatelet therapy (DAPT) for high bleeding risk patients.

In September 2021, Boston Scientific Corporation, a US-based biomedical engineering firm, acquired Devoro Medical, Inc. to focus on clot management and commercialization utilizing the WOLF Thrombectomy Platform developed by Devoro Medical. The innovative WOLF technology uses finger-like prongs to extract and remove thrombi in the arterial and venous systems swiftly. This acquisition enhances Boston Scientific's range of interventional strategies for thromboemboli, including the AngioJet Thrombectomy System and the EkoSonic Endovascular System (EKOS). Devoro Medical, Inc., a US-based company, is a developer of a medical device designed to restore blood flow.

Major companies operating in the bifurcation lesions market include Boston Scientific Corporation, Terumo Medical Corporation, Spectranetics Corporation, Medtronic PLC, Cardinal Health Inc., Cardinal Health Company, Abbott Laboratories, Biosensors International Group Ltd., B. Braun Melsungen AG, Cook Medical LLC, Cordis Corporation, Endologix Inc., W. L. Gore & Associates Inc., InspireMD Inc., Lombard Medical Technologies PLC, MicroPort Scientific Corporation, OrbusNeich Medical Company Limited, Biotronik SE & Co. KG, Cardionovum GmbH, Elixir Medical Corporation, Medinol Ltd., Meril Life Sciences Pvt. Ltd., MIV Therapeutics Inc., Natec Medical Ltd., Opto Circuits (India) Ltd., QualiMed Innovative Medizinprodukte GmbH, Sahajanand Medical Technologies Pvt. Ltd., Svelte Medical Systems Inc., Translumina GmbH, Vascular Concepts Limited, Vascular Solutions Inc., Veryan Medical Ltd., X-Cell Medical Inc., Zorion Medical Inc., Amaranth Medical Inc., Cardiomind Inc., Cardiva Medical Inc.

North America was the largest region in the bifurcation lesions market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bifurcation lesions market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the bifurcation lesions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The bifurcation lesions market includes revenues earned by proximal main branch (MB), distal MB and side branch (SB). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.